Altshuler Shaham Ltd Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Altshuler Shaham Ltd acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 27,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,414,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. TD Asset Management Inc increased its stake in shares of Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares during the period. Congress Asset Management Co. MA increased its holdings in Halozyme Therapeutics by 16.2% in the first quarter. Congress Asset Management Co. MA now owns 407,867 shares of the biopharmaceutical company’s stock valued at $16,592,000 after purchasing an additional 56,791 shares during the period. Boston Trust Walden Corp bought a new position in Halozyme Therapeutics during the 2nd quarter worth $23,211,000. Los Angeles Capital Management LLC lifted its holdings in Halozyme Therapeutics by 17.2% during the 1st quarter. Los Angeles Capital Management LLC now owns 121,000 shares of the biopharmaceutical company’s stock worth $4,922,000 after buying an additional 17,716 shares during the period. Finally, Norden Group LLC increased its stake in shares of Halozyme Therapeutics by 1,817.3% in the first quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company’s stock valued at $6,805,000 after buying an additional 158,559 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $55.12, for a total transaction of $551,200.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $9,269,861.12. The disclosure for this sale can be found here. Insiders sold a total of 84,881 shares of company stock valued at $4,888,184 over the last ninety days. 2.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent analyst reports. Benchmark reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $57.00 in a research note on Thursday. The Goldman Sachs Group increased their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Finally, TD Cowen boosted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $59.24 on Monday. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The business’s fifty day moving average is $58.40 and its 200 day moving average is $49.25. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $65.53. The stock has a market cap of $7.54 billion, a P/E ratio of 24.48, a P/E/G ratio of 0.57 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. During the same period last year, the company earned $0.68 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.